Patients with hematological abnormalities in HIV infection are seen regularly in the clinical setting. Malignant lymphomas, including aggressive forms of non-Hodgkin lymphoma (NHL), although decreased in incidence in the era of highly active antiretroviral therapy (HAART), are regularly seen and treated, as are other lymphoproliferative disorders such as Hodgkin lymphoma (HL), indolent NHL, Castleman disease, and paraproteinemias. Other blood disorders which occur with regularity include cytopenias, particularly anemia and thrombocytopenia, and immune thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP).

In this issue, we invite studies investigating hematologic diseases associated with HIV. Papers examining the epidemiology, clinical characteristics, predisposing factors, treatment, complications, and treatment outcomes will be considered. Review articles are welcome as are articles outlining guidelines for management. Topics of interest include, but are not limited to:

• Treatment regimens and outcomes for HIV-NHL and HL
• Role of immunotherapy in HIV-NHL
• Toxicity of lymphoma chemo-immunotherapy
• Role of high-dose chemotherapy and stem cell transplant in HIV-lymphoma
• Chemotherapy-HAART interactions
• Natural history, treatment, and outcome of indolent lymphoproliferative disorders and paraproteinemias
• Natural history, treatment, and outcome of non-clonal lymphoproliferative disorders
• Incidence, treatment, and outcome of HIV-ITP
• Incidence, treatment, and outcome of HIV-TTP
• Approach to HIV associated anemia

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ah/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable: